Loading…
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-119M | $-104M | $-70M | -22.6% | - | - |
| 2024 | $0M | $-104M | $-89M | $-73M | -28.7% | - | - |
| 2023 | $0M | $-83M | $-72M | $-61M | -29.1% | - | - |
| 2022 | $0M | $-39M | $-38M | $-33M | 49.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 38.79 | 83.53 | 104.55 | 119.66 |
| Operating Income | -38.79 | -83.53 | -104.55 | -119.66 |
| EBITDA | -38.58 | -83.23 | -104.24 | -119.39 |
| EBIT | -38.79 | -83.53 | -104.55 | -119.66 |
| Pretax Income | -37.66 | -71.58 | -88.79 | -103.69 |
| Tax Provision | 0 | 0 | 0.23 | 0 |
| Net Income | -37.66 | -71.58 | -89.02 | -103.69 |
| Net Income Common Stockholders | -37.66 | -71.58 | -89.02 | -103.69 |
| Total Expenses | 38.79 | 83.53 | 104.55 | 119.66 |
| Interest Income | 1.13 | 11.97 | 14.89 | 16.01 |
| Research And Development | 31.02 | 64.57 | 80.78 | 85.86 |
| Selling General And Administration | 7.77 | 18.95 | 23.78 | 33.80 |
| Normalized EBITDA | -38.58 | -83.23 | -105.11 | -119.39 |
| Normalized Income | -37.66 | -71.58 | -89.71 | -103.69 |
| Basic EPS | -0.92 | -2.01 | -1.89 | 0 |
| Diluted EPS | -0.92 | -2.01 | -1.89 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0.18 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0 |
| Total Unusual Items | 0 | 0 | 0.87 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0.87 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -37.66 | -71.58 | -89.02 | -103.69 |
| Reconciled Depreciation | 0.21 | 0.30 | 0.32 | 0.26 |
| Net Interest Income | 1.13 | 11.97 | 14.89 | 16.01 |
| Net Income From Continuing And Discontinued Operation | -37.66 | -71.58 | -89.02 | -103.69 |
| Total Operating Income As Reported | -38.79 | -83.53 | -104.55 | -119.66 |
| Diluted Average Shares | 41.10 | 35.55 | 47.07 | 0 |
| Basic Average Shares | 41.10 | 35.55 | 47.07 | 0 |
| Diluted NI Availto Com Stockholders | -37.66 | -71.58 | -89.02 | -103.69 |
| Net Income Including Noncontrolling Interests | -37.66 | -71.58 | -89.02 | -103.69 |
| Net Income Continuous Operations | -37.66 | -71.58 | -89.02 | -103.69 |
| Other Income Expense | 0 | -0.02 | 0.87 | -0.05 |
| Other Non Operating Income Expenses | 0 | -0.02 | 0 | -0.05 |
| Special Income Charges | 0 | 0 | 0.87 | 0 |
| Restructuring And Mergern Acquisition | 0 | 0 | -0.87 | 0 |
| Net Non Operating Interest Income Expense | 1.13 | 11.97 | 14.89 | 16.01 |
| Interest Income Non Operating | 1.13 | 11.97 | 14.89 | 16.01 |
| General And Administrative Expense | 7.77 | 18.95 | 23.78 | 33.80 |
| Other Gand A | 7.77 | 18.95 | 23.78 | 33.80 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Enliven Therapeutics, Inc.this co. | ELVN | $2.6B | - | 5.48 | -22.6% | -17.36 |
| Warby Parker Inc. | WRBY | $2.6B | 2147.00 | 7.15 | 0.4% | 56.61 |
| Tarsus Pharmaceuticals, Inc. | TARS | $2.6B | - | 7.52 | -19.3% | -32.50 |
| Immunome, Inc. | IMNM | $2.6B | - | 4.09 | -33.5% | -9.20 |
| Vera Therapeutics, Inc. | VERA | $2.6B |
| - |
| 4.23 |
| -49.6% |
| -6.09 |
| Heartflow, Inc. | HTFL | $2.5B | - | 8.38 | -38.8% | -37.97 |
| Celldex Therapeutics, Inc. | CLDX | $2.5B | - | 4.06 | -49.1% | -5.72 |
| Disc Medicine, Inc. | IRON | $2.5B | - | 3.38 | -28.7% | -7.48 |
| IDEAYA Biosciences, Inc. | IDYA | $2.5B | - | 2.41 | -11.1% | -11.82 |
| Peer Median | - | 2147.00 | 4.16 | -31.1% | -8.34 | |